Breaking News

FIMEA Renews Nanoform’s GMP License, Starts API Manufacture of Blockbuster Candidate

FIMEA fully reviewed Nanoform for compliance with its processes and adherence to GMP.

Nanoform Finland Plc, a nanoparticle medicine enabling company, announced that FIMEA (Finnish Medicines Agency) has completed another successful general good manufacturing practices (GMP) inspection of Nanoform. During the inspection on March 28, 2023, FIMEA fully reviewed Nanoform for compliance with its processes and adherence to GMP for the manufacture of multiple clinical active pharmaceutical ingredients (APIs). Nanoform received no critical or major observations during this inspection, ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters